FibroGen to initiate Phase II/III trial of roxadustat to treat MDS related anaemia in China

US-based biopharmaceutical firm FibroGen has secured approval from the China Food and Drug Administration (CFDA) to initiate a Phase II/III clinical trial of roxadustat to treat anaemia associated with lower risk myelodysplastic syndromes (MDS).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news